Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Mannkind Corporation Clear all
Terminated Phase 3 Interventional

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

NCT00332826
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

NCT00934414
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 11, 2026, 5:39 AM EDT
Recruiting Phase 2Phase 3 Interventional

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

NCT06535789
View directory record Official record
Conditions
Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions
Inhaled Technosphere Insulin
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 11, 2026, 5:39 AM EDT
Recruiting Phase 2 Interventional

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

NCT07224321
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere Insulin, Basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 11, 2026, 5:39 AM EDT
Withdrawn Not applicable Interventional

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

NCT01459133
View directory record Official record
Conditions
Diabetes
Interventions
Technosphere® Insulin Inhalation System
Drug
Lead sponsor
South Orange County Endocrinology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 11, 2026, 5:39 AM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Healthy Volunteers

NCT01365117
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Technosphere® Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 11, 2026, 5:39 AM EDT
Terminated No phase listed Observational

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

NCT01201928
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Comparator administered in parent trial, Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Fresno, California • Long Beach, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

NCT02527265
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Afrezza
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 11, 2026, 5:39 AM EDT
Completed No phase listed Observational

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

NCT00642681
View directory record Official record
Conditions
Diabetes Mellitus, Upper Respiratory Infection
Interventions
Technosphere Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tuscon, Arizona • Fresno, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Terminated Phase 3 Interventional Results available

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

NCT00642616
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Moderate Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Technosphere® Insulin, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Mission Hills, California • San Diego, California • Palm Harbor, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

NCT01021891
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Technosphere®/Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

NCT01490762
View directory record Official record
Conditions
Healthy
Interventions
Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

NCT00754624
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
17
States / cities
San Mateo, California • Santa Barbara, California • Middlebury, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT06880835
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control IQ + sleep or exercise activity with TI
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
No Longer Available No phase listed Expanded access

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

NCT01798914
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Montgomery, Alabama • Miami, Florida • Orland Park, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 11, 2026, 5:39 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Not listed Phase 4 Interventional

A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections

NCT04125082
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Diabetes and Glandular Disease Clinic
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 11, 2026, 5:39 AM EDT
Completed No phase listed Observational

A 2-Month Safety Follow-Up Trial

NCT00741429
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Technosphere Insulin Inhalation Powder, Comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge

NCT01902121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Technosphere® Insulin 10U + 20U, Technosphere® Insulin 30U
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 11, 2026, 5:39 AM EDT
Not listed Phase 4 Interventional

A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone

NCT03313960
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Afrezza plus One Drop | Premium, One Drop | Premium
Drug · Other
Lead sponsor
Informed Data Systems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 11, 2026, 5:39 AM EDT